echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > BrainPathol: Scientists have identified a biomarker used to diagnose a particular neurodegenerative disease, SAFB1.

    BrainPathol: Scientists have identified a biomarker used to diagnose a particular neurodegenerative disease, SAFB1.

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In a study published in the international journal, scientists from the University of Bristol and others have discovered a new type of pathology mechanism that exists during the onset of a variety of human neurodegenerative diseases, including Huntington's diseasePHOTO SOURCE: The researchers reveal how protein expression called proteins occur in the body of people with spinal microcephaly disorders ( ) and Huntington's disease , or is expected to serve as a common biomarker for the treatment of diseases with similar genetic backgroundsThe researchers say it is an important protein that controls gene regulation in the brain and is structurally similar to other proteins associated with age-related neurodegenerative diseasesIn the study, the researchers wanted to see whether proteins are directly related to the development of specific neurodegenerative diseases and then their analysis of expression in brain tissue after the death of patients with cerebral palpitations, multiple sclerosis, Parkinson's disease and control individuals found abnormal expression in nerve cells in the brain regions associated with cerebellum disorder and Huntington's diseaseSpinal alyocytosis and Huntington's disease are associated with a particular pathological manifestation, known as polyglutamamine dilation (amino acid repetition), which only occurs in both diseases, but the researchers did not find the same pathological manifestations in the body of patients with Parkinson's disease or multiple sclerosisThe researchers say the findings highlight a previously unknown mechanism for inducing diseases and may therefore serve as a diagnostic marker for diagnosing polyglutamamine dilated diseases such as Huntington's diseaseThe next step for researchers will also continue to delve into whether inhibited expression is expected to help improve patient performance, as the researchers will also study other neurodegenerative diseases, including Alzheimer's disease() Original origin: ():
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.